Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Positive Data On Bayer/Algeta's Alpharadin Could Accelerate Filing Timeline

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bayer AG/Algeta ASA have halted early a Phase III trial evaluating their first-in-class targeted radioactive drug Alpharadin (radium 223-chloride) for the treatment of symptomatic bone metastases in advanced prostate cancer patients based on positive interim results.

You may also be interested in...

Amgen's Bone Drug Xgeva Delays Pain From Prostate Cancer Metastases

Some physicians may be concerned by the incidence of osteonecrosis of the jaw reported in pivotal hormone-resistant prostate cancer trial.

Prostate Cancer Market Snapshot: More Than Provenge

The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.

Algeta Recruits Bayer To Deliver Prostate Cancer Drug Alpharadin To Market

Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts